Sunny Virmani

Arthur Brant, Chief Resident in Ophthalmology at Stanford, and Sunny Virmani, Group Product Manager at Google, dive into the potential of AI in diabetic retinopathy screening. They discuss a groundbreaking study comparing AI's effectiveness to human evaluations, highlighting both opportunities and disparities in screening access. The conversation addresses challenges such as model drift and accountability in AI use. They stress the importance of ongoing monitoring and innovative solutions to improve patient care, especially in underserved areas.

Arthur Brant, Chief Resident in Ophthalmology at Stanford, and Sunny Virmani, Group Product Manager at Google, delve into the revolutionary role of AI in diabetic retinopathy screening. They discuss a study assessing AI's effectiveness compared to human graders and highlight the urgent need for improved screening, especially in underserved areas. The duo also tackles real-world challenges such as image quality and technician training. With a focus on proactive collaboration in AI deployment, they emphasize the importance of adapting technology to local healthcare settings.